These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24621839)

  • 1. Prolongation of the QTc interval predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy.
    Gray B; Ingles J; Medi C; Semsarian C
    JACC Heart Fail; 2013 Apr; 1(2):149-55. PubMed ID: 24621839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy.
    Earle N; Ingles J; Bagnall RD; Gray B; Crawford J; Smith W; Shelling AN; Love DR; Semsarian C; Skinner JR
    J Cardiovasc Electrophysiol; 2015 Dec; 26(12):1346-51. PubMed ID: 26332198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST-segment depression as a risk factor in hypertrophic cardiomyopathy.
    Haghjoo M; Mohammadzadeh S; Taherpour M; Faghfurian B; Fazelifar AF; Alizadeh A; Rad MA; Sadr-Ameli MA
    Europace; 2009 May; 11(5):643-9. PubMed ID: 19164362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
    Dinshaw L; Münch J; Dickow J; Lezius S; Willems S; Hoffmann BA; Patten M
    Clin Res Cardiol; 2018 Feb; 107(2):130-137. PubMed ID: 28965260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
    J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.
    Woo A; Monakier D; Harris L; Hill A; Shah P; Wigle ED; Rakowski H; Rozenblyum E; Cameron DA
    Heart; 2007 Sep; 93(9):1044-5. PubMed ID: 17699173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
    Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
    Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
    Magnusson P; Gadler F; Liv P; Mörner S
    Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
    Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
    Campbell M; Moore JP; Sreeram N; von Alvensleben JC; Shah A; Batra A; Law I; Sanatani S; Thomas V; Nik-Ahd F; Williams S; Nosavan N; Maldonado J; Hart A; Nguyen T; Balaji S
    Heart Rhythm; 2018 May; 15(5):703-707. PubMed ID: 29309839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy.
    Zhang N; Cheng S; Niu H; Gu M; Peng H; Sun Z; Liu X; Deng Y; Chen X; Hua W
    Front Cardiovasc Med; 2022; 9():882662. PubMed ID: 35647065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.